Empagliflozin to Prevent Post-Operative Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 492 participants.

Also called NCT06124937

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 492 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06124937
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06124937. Randomized; quadruple masking; primary purpose prevention. Start 2023-11-07 (actual); primary completion 2024-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Acronym
EMPOAF
Condition
Post-operative Atrial Fibrillation
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
Rajaie Cardiovascular Medical and Research Center (class: other)
Collaborator
Tehran Heart Center (class: other)

Record details

Record id
cardio:ct-nct06124937
Content hash
48b16191b64244c3b4cb6b41a2f2e456decdd83169ebbc6522d6c2bebe7819c2